Understanding the effect of mutations on cell behaviour in blood disorders through mathematical modelling and computational analysis
Understanding the effect of mutations on cell behaviour in blood disorders through mathematical modelling and computational analysis
批准号:
2887435
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Clonal expansion is particularly well studied in haematopoiesis, the production of blood cells. Clonal haematopoiesis (CH) is the expansion of mutations in haematopoietic stem cells (HSCs) that become detectable in blood or bone marrow of healthy aged individuals. More than 10% of the population over 65 years of age are affected by CH. CH is associated with increased risk for all- cause mortality, heart disease and ischaemic stroke. In 2022, CH has been recognised by the World Health Organization as a precursor myeloid disease state.CH constitutes a known risk factor for myelodysplastic syndromes (MDS), a group of blood cancers in which the maturation of blood stem cells in the bone marrow and their downstream production of differentiated blood cells is impaired. Mutations in spliceosome components, with SF3B1 as one of the most common events, play a significant role in driving clonal expansion and disease progression. Additionally, SF3B1 is a particularly interesting genetic driver due to its dual risk profile, constituting a protective event in MDS with ring sideroblasts (MDS-RS) and yet having a dismal prognosis when co- occurring in MDS with 5q deletion. The reasoning for these distinct effects and the role of different SF3B1 mutations in MDS expansion and progression are currently unknown.Risk prognosis is currently calculated as part of a diagnostic sequencing approach, with few studies centred on what factors drive clonal expansion over time. Being able to predict the clonal expansion of different mutations and understanding how co-mutations interact to modify disease risk could facilitate monitoring of MDS in individuals for the stratification of risk. More research is required to determine the mechanisms by which certain clones can outcompete others in the bone marrow and blood production.The Schumacher group has recently shown that mutations in different genes can have different expansion rates. This insight was enabled by the availability of longitudinal sequencing data from healthy aged individuals in combination with mathematical models of clonal expansion to make sense of such data. We now plan to apply this approach to quantify and understand the clonal expansion of SF3B1 mutations in MDS. As MDS with SF3B1 mutations are typically lower risk they are closer to the pre-malignant status of CH than other blood malignancies and therefore our methods may be applicable with only small modifications.The Hellström Lindberg group has established a well-annotated biobank of >1200 consecutive patients with MDS and related disorders. One focus of the group lies on MDS with mutations in the gene SF3B1, for which they do serial sampling over time. These data provide the ideal test-bed for extending theapplicability of recent mathematical models, guided by the clinical expertise of the Hellström Lindberg group. The group has also established a 3D culture system to study the clonal expansion of patient-derived cells with known mutations in vitro. We will systematically quantify the kinetics and variability of expansion of selected SF3B1 mutations. This will serve as validation of the in vivo findings and enable the further development of mathematical models to include different potential mechanisms of clonal expansion, the predictions of which can be tested experimentally.Aims1. Adapt mathematical models of clonal haematopoiesis to make them applicable to data from low risk MDS patients.2. Test whether rate of clonal expansion of SF3B1 mutations is specific to the mutational variant, hotspot location within the gene, or other factors (e.g., from clinical metadata).3. Verify differences in clonal expansion using 3D culture system and quantify variability of kinetics.4. Adapt mathematical models to make them applicable to in vitro data from 3D culture system.5. Determine the mechanism of how SF3B1 mutations cause clonal expansion using a combination of in vitro experiments and mathematical models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Crocin 抑制 Hartley 豚鼠早期骨关节炎发生的
作用机制研究
-
批准号:TGD24H060003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:李恒
-
依托单位:
超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
-
批准号:82371103
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:阮静
-
依托单位:
LINC00673调控HIF-1α促进Warburg effect在子宫内膜蜕膜化中的作用和机制研究
-
批准号:82060281
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2020
-
负责人:朱元昌
-
依托单位:
PKM2调控H2B泛素化修饰的分子机制及其在肿瘤代谢中的作用研究
-
批准号:81773009
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2017
-
负责人:陈苏
-
依托单位:
DAPK乙酰化修饰及其调控肝癌生长新机制的研究
-
批准号:81772634
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2017
-
负责人:张海涛
-
依托单位:
(宫颈)癌前病变的Warburg-like effect与糖代谢重编程机制研究
-
批准号:31670788
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2016
-
负责人:陈尚武
-
依托单位:
基于太赫兹光谱近场成像技术的应力场测量方法
-
批准号:11572217
-
项目类别:面上项目
-
资助金额:120.0万元
-
批准年份:2015
-
负责人:王志勇
-
依托单位:
茉莉酸甲酯通过SP1/c-Myc调控PKM2表达靶向抑制膀胱癌细胞能量代谢的研究
-
批准号:81402113
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:肖行远
-
依托单位:
低杂波加热的全波解TORIC数值模拟以及动理论GeFi粒子模拟
-
批准号:11105178
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:杨程
-
依托单位:
铁磁、半金属-超导异质结中电子输运的理论研究
-
批准号:60971053
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2009
-
负责人:周世平
-
依托单位: